

Israel Chemicals (ICL.TA)

RESULTS

54.61 (from 55.20) 54.50¹ 19,048.61

NEUTRAL*

Market cap. (US\$ m) 19,048.61 Enterprise value (US\$ m) 19,971.3
*Stock ratings are relative to the relevant country benchmark.

Rating

Price (22 Nov 10, NIS)

¹Target price is for 12 months.

Target Price (NIS)

Research Analysts

Semyon Mironov

7 495 662 8510 semyon.mironov@credit-suisse.com

Mikhail Priklonsky

7 495 662 8511 mikhail.priklonsky@credit-suisse.com

3Q2010 financial results review

We reiterate Neutral rating however decrease TP for ICL from ILS55.2/sh to ILS54.5/sh on the back of weaker than expected 3Q2010 financial results.

3Q2010A EBITDA was US\$374m vs. our estimate of US\$400m due to higher than we expected operating costs at potash operations. ICL partially reduced potash production in Europe during summer holidays and, as a result of fixed maintenance expenses, operating cash costs per tonne of potash was above our expectations, while other business segments were in line.

Figure 1: ICL – 3Q2010 financial results review in millions US\$, unless otherwise stated

	3Q2010A 30	Q2010E CS	Act./ CS 3	Q10E Cons	Act./ Cons
Revenue	1,394	1,436	-3%	1,448	-4%
EBITDA	374	400	-6%	na	na
EBITDA margin	27%	28%			
Operating income	319	345	-7%	na	na
Net income	243	230	6%	266	-9%
Potash sales, kt	1,212	1,178	3%	na	na

Source: Company data, Reuters Consensus, Credit Suisse estimates

ICL remains one of the most expensive potash producers globally trading on 2011E/12E EV/EBITDA of 11.4x/10.4x vs. major developed producers that are trading on the average of 10.4x/9.0x.

The risk to ICL's earnings from the recently discussed in press increase of royalty tax from 5% to 10% should be in the range of only US\$10-15m (potential increase in royalty should be applicable to volumes ICL produces in Israel in excess of 3mt, what at max levels of production levels would equal to c0.8mt).

TP of ILS54.5/sh is based on a target 2011E EV/EBITDA of 11x. Our DCF-based valuation returns ILS50.1/sh fair equity value per share estimate.

Year	12/09A	12/10E	12/11E	12/12E
Revenue (US\$ m)	4,554.3	5,706.2	5,964.0	6,382.4
EBITDA (ÚS\$ m)	1,142.79	1,572.98	1,736.59	1,929.68
Net Income (US\$ m)	774.3	1,029.1	1,176.8	1,320.6
CS adj. EPS (US\$)	0.61	0.81	0.93	1.04
Prev. EPS (US\$)	_	_	0.95	1.05
ROIC (%)	19.48	26.34	27.41	29.07
P/E (adj., x)	24.60	18.51	16.19	14.42
P/E rel. (%)	145.2	136.9	133.9	140.4
EV/EBITDA	17.2	12.7	11.5	10.3
Dividend (12/10E, NIS)	0.57	IC (12/10E, US\$	m)	4,226.9
Dividend yield (%)	1.0	EV/IC		4.7
Net debt (12/10E, US\$ m)	1,369.7	Current WACC		11.0
Net debt/equity (12/10E, %)	52.5	Free float (%)		32.7
BV/share (12/10E, US\$)	2.0	Number of share	es (m)	1,266.88



The price relative chart measures performance against the Israel TA100 index which closed at 1167.75 on 22/11/10 on 22/11/10 the spot exchange rate was NIS4.95/Eu 1. - Eu .73/US\$1

Performance Over	1 M	3M	12M
Absolute (%)	-3.4	9.2	7.0
Relative (%)	-3.0	-0.2	-8.6

DISCLOSURE APPENDIX CONTAINS ANALYST CERTIFICATIONS AND THE STATUS OF NON-US ANALYSTS. U.S. Disclosure: Credit Suisse does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.



Figure 2: ICL summary page

BASICS					
Company Name Is	srael Chemicals		Sector: Fertilizers	Ticker:	ICL.TA
Current share price (IL	.S/sh)		54.6	BBG:	ICL TA
Target share price (ILS	S/sh)		54.5	Potential upside:	0%
Rating			Neutral		
Current Market Cap (U	IS\$m)		19,049	Outs (m):	1,266.884
YE10E Net Debt (US\$	m)		1,370	(as of YE1Q10)	
Current EV (US\$m)			19,971	WACC:	11.0%
Free float	(in %): 33%	(in US\$m):	6,229		
Av daily trading volume	e (YTD, US\$m)		US\$40m	•	

RODUCTION DATA	2007A	2008A	2009A	2010E	2011E	2012E
apacity, Mt						
Potash	5. 1	5.1	5.1	5.4	5.4	5.7
Phosphates	3.0	3.6	3.6	3.8	4.1	4.3
Compound fertilizers	1.8	1.8	1.8	1.8	2.0	2.0
roduction, Mt						
Potash	5.1	5.0	4.0	4.9	5.2	5.4
Phosphates	3.1	3.1	2.7	3.3	3.4	3.8
Compound fertilizers	1.8	1.5	0.9	1.7	1.8	1.9
ales external, Mt						
Potash	5.2	4.5	2.6	5.2	4.9	5.4
Phosphates	0.3	0.6	0.6	0.7	0.7	0.8
Compound fertilizers	1.8	1.4	1.1	1.7	1.8	1.9
ventories, Mt						
Potash	1.3	1.5	2.9	1.7	1.8	1.5

PRICES DATA	2007A	2008A	2009A	2010E	2011E	2012E
Wght. av. potash price	237	542	512	367	414	434
China, FOB, US\$/t	170	575	485	350	385	405
India, CFR, US\$/t	240	489	543	368	385	405
Spot, CFR, US\$/t	237	695	575	358	421	441
Phosphates, US\$/t		953	338	480	485	440
Compound fertilizers, US\$/t		821	408	533	539	489

Revenue							
Revenue 4,103 6,904 4,554 5,706 5,964 6,382 COGS (+ D/A) 2,556 3,449 2,718 3,279 3,369 3,489 GBAA 804 1,120 898 1,069 1,088 1,207 EBITDA 909 2,565 1,143 1,573 1,737 1,930 EBIT Amargin 22% 37% 25% 28% 29% 30% EBIT Amargin 22% 335 938 1,359 1,506 1,866 Net profit - adjusted 550 1,994 774 1,029 1,177 1,321 EPS 0.43 0.76	FINANCIAL STATEMENTS	2007A	2008A	2009A	2010E	2011E	2012E
2,556 3,449 2,718 3,279 3,369 3,489 3,68A 804 1,120 898 1,069 1,088 1,207 BITDA 909 2,565 1,143 1,573 1,737 1,930 BITDA 909 2,565 1,143 1,575 1,566 1,686 BITDA 909 2,565 1,143 1,569 1,566 1,686 BITDA 909 704 1,029 1,177 1,321 BITDA 909 704 1,029 1,177 1,321 BITDA 909 909 909 909 909 909 909 BITDA 909 909 909 909 909 909 909 909 909 BITDA 909 90	Extractions from Income State	ement					
BITDA 909 2,565 1,143 1,573 1,737 1,930 22% 37% 25% 29% 29% 30% 25% 21% 29% 30% 25% 21% 29% 30% 25% 21% 29% 30% 25% 21% 29% 30% 25% 21% 29% 30% 25% 21% 29% 30% 25% 21% 29% 30% 25% 21% 29% 30% 25% 21% 29% 30% 25% 21% 20% 29% 30% 25% 20% 29% 30% 25% 20% 29% 30% 25% 20% 29% 30% 25% 20% 29% 30% 25% 20% 29% 30% 25% 20% 29% 30% 25% 20% 29% 30% 25% 20% 29% 30% 25% 20% 29% 30% 25% 20% 20% 20% 20% 20% 20% 20% 20% 20% 20	Revenue	4,103	6,904	4,554	5,706	5,964	6,382
### BITDA 909 2,565 1,143 1,573 1,737 1,930 ### BIT 743 2,335 938 1,359 1,506 1,686 ### Interest expense 117 178 83 126 58 58 ### Interest expense 117 178 83 126 58 58 ### Interest expense 117 178 83 126 58 58 ### Interest expense 117 178 83 126 58 58 ### Interest expense 117 178 83 126 58 58 ### Interest expense 117 178 83 126 58 58 ### Interest expense 117 178 83 126 58 58 ### Interest expense 117 178 83 126 58 58 ### Interest expense 117 178 83 126 58 58 ### Interest expense 117 178 83 126 58 58 ### Interest expense 117 178 83 126 58 58 ### Interest expense 117 178 83 126 58 58 ### Interest expense 117 178 83 126 58 58 ### Interest expense 118 1.57 0.61 0.81 0.93 1.04 ### Interest expense 1.04 ### Interest expense 1.04 0.81 0.93 1.04 ### Interest expense 1.04 0.04 0.04 0.04 0.04 ### Interest expense 1.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04	COGS (+ D/A)	2,556	3,449	2,718	3,279	3,369	3,489
EBITDA margin 22% 37% 25% 28% 29% 30% EBIT	SG&A	804	1,120	898	1,069	1,088	1,207
PS	EBITDA	909	2,565	1,143	1,573	1,737	1,930
Note Part	EBITDA margin	22%	37%	25%	28 %	29%	30%
See	ЕВІТ	743	2,335	938	1,359	1,506	1,686
PS 0.43 1.57 0.61 0.81 0.93 1.04 OPS 0.43 0.76 0.38 0.57 0.46 0.52 Extractions from Balance Sheet Cash and cash equivalents 58 215 258 143 563 983 overstments 221 345 422 447 447 447 447 OPS 0.59 0.59 0.59 0.59 0.59 0.59 0.59 0.59	nterest expense	117	178	83	126	58	58
OPS 0.43 0.76 0.38 0.57 0.46 0.52 Extractions from Balance Sheet Cash and cash equivalents 58 215 258 143 563 983 Investments 221 345 422 447 447 447 PP&E 1,804 1,907 2,093 2,183 2,278 2,410 Short-term debt 623 412 104 26 26 26 Cong-term debt 627 909 700 940 940 940 Working capital 1,867 2,511 2,795 2,608 3,199 3,861 Accounts receivable 962 1,504 1,884 1,733 1,119 1,160 1,219 Accounts payable 428 448 470 471 489 513 Extractions from Cash Flow Statement 248 448 470 471 489 513 Extractions from Cash Flow Statement 248 448 470 471	Net profit - adjusted	550	1,994	774	1,029	1,177	1,321
Extractions from Balance Sheet Sector of the Extractions from Balance Sheet Sector of the Extractions from Balance Sheet Sector of the Extractions from Balance Sheet 143 563 983 charmonic Sheet 221 345 422 447 447 447 charmonic Sheet 1,804 1,907 2,093 2,183 2,278 2,410 Short-term debt 623 412 104 26 26 26 cong-term debt 627 909 700 940 940 940 cquity 1,867 2,511 2,795 2,608 3,199 3,861 Norking capital 1,504 1,884 1,733 1,740 1,815 1,926 executity receivable 962 1,054 970 1,092 1,144 1,221 executity payable 428 448 470 471 489 513 extractions from Cash Flow Statement 965 1,994 774 1,029 1,177 1,321 extractions from Cash Flow	EPS	0.43	1.57	0.61	0.81	0.93	1.04
Cash and cash equivalents 58 215 258 143 563 983 Investments 221 345 422 447 447 447 PP&E 1,804 1,907 2,093 2,183 2,278 2,410 Short-term debt 623 412 104 26 26 26 cong-term debt 627 909 700 940 940 940 Equity 1,867 2,511 2,795 2,608 3,199 3,861 Norking capital 1,504 1,884 1,733 1,740 1,815 1,926 eventories 971 1,278 1,233 1,119 1,160 1,219 Accounts receivable 962 1,054 970 1,092 1,144 1,221 Accounts payable 428 448 470 471 489 513 Extractions from Cash Flow Statement Statement Statement 48 470 471 429 244 <td>DPS</td> <td>0.43</td> <td>0.76</td> <td>0.38</td> <td>0.57</td> <td>0.46</td> <td>0.52</td>	DPS	0.43	0.76	0.38	0.57	0.46	0.52
Number 1,804 1,907 2,093 2,183 2,278 2,410 Short-term debt 623 412 104 26 26 26 Cong-term debt 627 909 700 940 940 940 Equity 1,867 2,511 2,795 2,608 3,199 3,861 Norking capital 1,504 1,884 1,733 1,740 1,815 1,926 Inventories 971 1,278 1,233 1,119 1,160 1,219 Accounts receivable 962 1,054 970 1,092 1,144 1,221 Accounts payable 428 448 470 471 489 513 Extractions from Cash Flow Statement Not income 553 1,994 774 1,029 1,177 1,321 DD&A 166 230 205 214 230 244 Other adjustments 5 -85 97 -16 0 0 NC change -151 -254 124 -33 -76 -111 Net operating CF 574 1,884 1,200 1,194 1,331 1,453 Acquisitions 0 0 0 0 0 0 Purchases of PP&E -189 -320 -346 -314 -325 -375 Other investment CF -291 -191 -98 -42 0 0 Other investment CF -291 -191 -98 -42 0 0 Other adjustment -291 -191 -98 -42 0 0 Other investment CF -291 -191 -98 -42 0 0 Other investment CF -291 -191 -98 -42 0 0 Other adjustment -291 -29	Extractions from Balance She	eet					
PREE 1,804 1,907 2,093 2,183 2,278 2,410 Short-term debt 623 412 104 26 26 26 cong-term debt 627 909 700 940 940 940 Equity 1,867 2,511 2,795 2,608 3,199 3,861 Norking capital 1,504 1,884 1,733 1,740 1,815 1,926 Inventories 971 1,278 1,233 1,119 1,160 1,219 Accounts receivable 962 1,054 970 1,092 1,144 1,221 Accounts payable 428 448 470 471 489 513 Extractions from Cash Flow Statement Statement Statement 180 230 205 214 230 244 Other adjustments 5 -85 97 -16 0 0 WC change -151 -254 124 -33 -76 -111 <td>Cash and cash equivalents</td> <td>58</td> <td>215</td> <td>258</td> <td>143</td> <td>563</td> <td>983</td>	Cash and cash equivalents	58	215	258	143	563	983
Short-term debt 623 412 104 26 26 26 cong-term debt 627 909 700 940 940 940 Equity 1,867 2,511 2,795 2,608 3,199 3,861 Norking capital 1,504 1,884 1,733 1,740 1,815 1,926 Inventories 971 1,278 1,233 1,119 1,160 1,219 Accounts receivable 962 1,054 970 1,092 1,144 1,221 Accounts payable 428 448 470 471 489 513 Extractions from Cash Flow Statement Statement Statement Statement 1,029 1,177 1,321 DD&A 166 230 205 214 230 244 Other adjustments 5 -85 97 -16 0 0 NC change -151 -254 124 -33 -76 -111 Net opera	nvestments	221	345	422	447	447	447
Description Congress of PP&E Congress of PP&E	PP&E	1,804	1,907	2,093	2,183	2,278	2,410
1,867 2,511 2,795 2,608 3,199 3,861	Short-term debt	623	412	104	26	26	26
Norking capital 1,504 1,884 1,733 1,740 1,815 1,926 Inventories 971 1,278 1,233 1,119 1,160 1,219 Accounts receivable 962 1,054 970 1,092 1,144 1,221 Accounts payable 428 448 470 471 489 513 Extractions from Cash Flow Statement 186 230 205 214 230 244 DD&A 166 230 205 214 230 244 Dther adjustments 5 -85 97 -16 0 0 VC change -151 -254 124 -33 -76 -111 Net operating CF 574 1,884 1,200 1,194 1,331 1,453 Acquisitions 0 0 0 0 0 0 0 Purchases of PP&E -189 -320 -346 -314 -325 -375 Other inv	ong-term debt	627	909	700	940	940	940
Numertories 971 1,278 1,233 1,119 1,160 1,219 1,000 1,219 1,000 1,000 1,144 1,221 1,221 1,000 1,000 1,144 1,221 1,000 1,000 1,144 1,221 1,000 1,000 1,144 1,221 1,000 1,000 1,144 1,221 1,000 1,144 1,221 1,000 1,144 1,021 1,177 1,321 1,000 1,177 1,321 1,000 1,177 1,321 1,000 1,000 1,177 1,321 1,000	quity	1,867	2,511	2,795	2,608	3,199	3,861
occounts receivable 962 1,054 970 1,092 1,144 1,221 ccounts payable 428 448 470 471 489 513 Extractions from Cash Flow Statement 553 1,994 774 1,029 1,177 1,321 IDB&A 166 230 205 214 230 244 Wither adjustments 5 -85 97 -16 0 0 VC change -151 -254 124 -33 -76 -111 Vet operating CF 574 1,884 1,200 1,194 1,331 1,453 cquisitions 0 0 0 0 0 0 0 turchases of PP&E -189 -320 -346 -314 -325 -375 their investment CF -291 -191 -98 -42 0 0	Vorking capital	1,504	1,884	1,733	1,740	1,815	1,926
Accounts payable 428 448 470 471 489 513 Extractions from Cash Flow Statement Net income 553 1,994 774 1,029 1,177 1,321 DD&A 166 230 205 214 230 244 Dther adjustments 5 -85 97 -16 0 0 NC change -151 -254 124 -33 -76 -111 Vet operating CF 574 1,884 1,200 1,194 1,331 1,453 Acquisitions 0 0 0 0 0 0 0 Durchases of PP&E -189 -320 -346 -314 -325 -375 Dther investment CF -291 -191 -98 -42 0 0	nventories	971	1,278	1,233	1,119	1,160	1,219
Extractions from Cash Flow Statement Met income 553 1,994 774 1,029 1,177 1,321 DD&A 166 230 205 214 230 244 Dther adjustments 5 -85 97 -16 0 0 VC change -151 -254 124 -33 -76 -111 Vet operating CF 574 1,884 1,200 1,194 1,331 1,453 vcquisitions 0 0 0 0 0 0 0 vcriciases of PP&E -189 -320 -346 -314 -325 -375 Other investment CF -291 -191 -98 -42 0 0	Accounts receivable	962	1,054	970	1,092	1,144	1,221
Net income 553 1,994 774 1,029 1,177 1,321 DD&A 166 230 205 214 230 244 Other adjustments 5 85 97 -16 0 0 VC change -151 -254 124 -33 -76 -111 Vet operating CF 574 1,884 1,200 1,194 1,331 1,453 vcquisitions 0 0 0 0 0 0 0 vcrchases of PP&E -189 -320 -346 -314 -325 -375 Other investment CF -291 -191 -98 -42 0 0			448	470	471	489	513
DD&A 166 230 205 214 230 244 Other adjustments 5 -85 97 -16 0 0 NC change -151 -254 124 -33 -76 -111 Net operating CF 574 1,884 1,200 1,194 1,331 1,453 Acquisitions 0 0 0 0 0 0 0 Purchases of PP&E -189 -320 -346 -314 -325 -375 Other investment CF -291 -191 -98 -42 0 0							
Other adjustments 5 -85 97 -16 0 0 VC change -151 -254 124 -33 -76 -111 Vet operating CF 574 1,884 1,200 1,194 1,331 1,453 Acquisitions 0 0 0 0 0 0 0 Purchases of PP&E -189 -320 -346 -314 -325 -375 Other investment CF -291 -191 -98 -42 0 0							
NC change -151 -254 124 -33 -76 -111 Net operating CF 574 1,884 1,200 1,194 1,331 1,453 Acquisitions 0 0 0 0 0 0 0 Purchases of PP&E -189 -320 -346 -314 -325 -375 Other investment CF -291 -191 -98 -42 0 0							
Net operating CF 574 1,884 1,200 1,194 1,331 1,453 Acquisitions 0 0 0 0 0 0 0 Purchases of PP&E -189 -320 -346 -314 -325 -375 Other investment CF -291 -191 -98 -42 0 0	•						
Acquisitions 0 0 0 0 0 0 0 Purchases of PP&E -189 -320 -346 -314 -325 -375 Other investment CF -291 -191 -98 -42 0 0	VC change	-151	-254	124	-33	-76	-111
Purchases of PP&E -189 -320 -346 -314 -325 -375 Other investment CF -291 -191 -98 -42 0 0	Net operating CF	574	1,884	1,200	1, 194	1,331	1,453
Other investment CF -291 -191 -98 -42 0 0	Acquisitions	0	0	0	0	0	0
	Purchases of PP&E	-189	-320	-346	-314	-325	-375
Net investment CF -480 -511 -444 -356 -325 -375	Other investment CF	-291	-191	-98	-42	0	0
	Net investment CF	-480	-511	-444	-356	-325	-375

	RIPTION

3Q10A 4Q10E

1.0

0.5

1.0

0.8

0.4

1.2

0.2

1.8

3Q10A

360

350

370

358

470

522

1.3

1.0

0.5

1.2

0.9

0.4

1.2

0.2 0.4

1.7

4Q10E

361

350

370

358

550

611

4Q10E

813

28%

2,183

26

940

2,608

1,740

1,119

1,092

471

247

270

56

0

-219

84

0

-77

-77

55

0

Israel Chemicals is large diversified fertilizers and chemicals producer with production facilities located in Israel and Europe. Total production capacities are: potash - 5.1~mt, phosphate rock - 3.0~mt and compound fertilizers - 1.8~mt.

INVESTMENT	CASE
PROS	- One of the lowest costs potash producers globally
<u> </u>	- Ability to store in the desert
CONS	- ICL is not a pure potash producer and consolidated profitability is affected by low marginal phosphate and other businesses.

CURRENT VALUATIONS	2010E	2011E	2012E
EV/EBITDA	12.7	11.5	10.3
P/E	18.5	16.2	14.4
EV/Sales	3.5	3.3	3.1
EV/IC	4.7	4.5	4.3
P/B	7.3	6.0	4.9


EM PEERS CURRENT VALUATIONS	2010E	2011E	2012E
EV/EBITDA	15.3	10.4	9.0
P/E	29.8	18.1	16.6

TARGET PRICE CALCULATION	Weight	Value
2011E EV/EBITDA of: 11x	100%	54.5
DCF @ 11%, ILS/sh	0%	50.1
USD/ILS current		3.80
Target price, II S/sh		54.5

AT TARGET PRICE	2010E	2011E	2012E
EV/EBITDA at target	12.1	11.0	9.9
P/E at target	17.7	15.4	13.8
P/B at target	7.0	5.7	4.7

RETURNS	2007A	2008A	2009A	2010E	2011E	2012E
ROIC	21%	58%	19%	26%	27%	29%
ROE	29%	79%	28%	39%	37%	34%





Operating income break-down, US\$m					
2,500	2,481 254				
2,000 -	105				4.000
	616		1,363	1,506	1,686
원 1,500 - 텔 1,000 -		1,007	206	217 184	225 191 110
	1,548	163	190 139	143	
\$	1,346	3월			4.400

Prices as of 22 November 2010. Source: Company data, the BLOOMBERG PROFESSIONAL™ service, Credit Suisse estimates

787 1,007 1,035 1,106

2 Israel Chemicals (ICL.TA)



Companies Mentioned (Price as of 22 Nov 10) Israel Chemicals (ICL.TA, NIS5461.00, NEUTRAL, TP NIS54.50)

Disclosure Appendix

Important Global Disclosures

The analysts identified in this report each certify, with respect to the companies or securities that the individual analyzes, that (1) the views expressed in this report accurately reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.

See the Companies Mentioned section for full company names.

3-Year Price, Target Price and Rating Change History Chart for ICL.TA

ICL.TA Date	Closing Price (NIS)	Target Price (NIS)		108
10-Jul-08	71	109	X	88
29-Sep-08	51.48	101		78 ————————————————————————————————————
30-Oct-08	35.89	73		68 68_
24-Feb-09	31.36	64		58
11-Mar-09	33.15	62		58 55 ■525 ★■ 52 ■55 ■ 52 ■55 ■
10-Jun-09	45	74		38
02-Jul-09	38.99	55		28 - Lym Arthur May 1
25-Aug-09	46.41	52		NIS ₁₈ 10-Jul-08 ♦
14-Sep-09	41.4	54		
02-Dec-09	51.35		N	Windry Windry Windry Stilling Star of Findry Findry Windry Windry Star of Findry Findry Windry Windry Stilling Star
26-Jan-10	49.57	50		
17-Feb-10	48.04	51		— Closing Price ■ Target Price ♦ Initiation/Assumption ◆ Rating
25-Mar-10	50.5	53.4		O=Outperform; N=Neutral; U=Underperform; R=Restricted; NR=Not Rated; NC=Not Covered
12-Aug-10	48.2	51.9		
07-Oct-10	52.5	55.2		

The analyst(s) responsible for preparing this research report received compensation that is based upon various factors including Credit Suisse's total revenues, a portion of which are generated by Credit Suisse's investment banking activities.

Analysts' stock ratings are defined as follows:

Outperform (O): The stock's total return is expected to outperform the relevant benchmark* by at least 10-15% (or more, depending on perceived risk) over the next 12 months.

Neutral (N): The stock's total return is expected to be in line with the relevant benchmark* (range of ±10-15%) over the next 12 months.

Underperform (U): The stock's total return is expected to underperform the relevant benchmark* by 10-15% or more over the next 12 months.

*Relevant benchmark by region: As of 29th May 2009, Australia, New Zealand, U.S. and Canadian ratings are based on (1) a stock's absolute total return potential to its current share price and (2) the relative attractiveness of a stock's total return potential within an analyst's coverage universe**, with Outperforms representing the most attractive, Neutrals the less attractive, and Underperforms the least attractive investment opportunities. Some U.S. and Canadian ratings may fall outside the absolute total return ranges defined above, depending on market conditions and industry factors. For Latin American, Japanese, and non-Japan Asia stocks, ratings are based on a stock's total return relative to the average total return of the relevant country or regional benchmark; for European stocks, ratings are based on a stock's total return relative to the analyst's coverage universe**. For Australian and New Zealand stocks a 22% and a 12% threshold replace the 10-15% level in the Outperform and Underperform stock rating definitions, respectively, subject to analysts' perceived risk. The 22% and 12% thresholds replace the +10-15% and -10-15% levels in the Neutral stock rating definition, respectively, subject to analysts' perceived risk.

**An analyst's coverage universe consists of all companies covered by the analyst within the relevant sector.

Restricted (R): In certain circumstances, Credit Suisse policy and/or applicable law and regulations preclude certain types of communications, including an investment recommendation, during the course of Credit Suisse's engagement in an investment banking transaction and in certain other circumstances.

Volatility Indicator [V]: A stock is defined as volatile if the stock price has moved up or down by 20% or more in a month in at least 8 of the past 24 months or the analyst expects significant volatility going forward.

Analysts' coverage universe weightings are distinct from analysts' stock ratings and are based on the expected performance of an analyst's coverage universe* versus the relevant broad market benchmark**:

Overweight: Industry expected to outperform the relevant broad market benchmark over the next 12 months.

Market Weight: Industry expected to perform in-line with the relevant broad market benchmark over the next 12 months.

Underweight: Industry expected to underperform the relevant broad market benchmark over the next 12 months.

*An analyst's coverage universe consists of all companies covered by the analyst within the relevant sector.

Israel Chemicals (ICL.TA)

^{**}The broad market benchmark is based on the expected return of the local market index (e.g., the S&P 500 in the U.S.) over the next 12 months.



Credit Suisse's distribution of stock ratings (and banking clients) is:

Global Ratings Distribution

Outperform/Buy* 45% (61% banking clients)
Neutral/Hold* 41% (60% banking clients)
Underperform/Sell* 12% (53% banking clients)

Restricted 2%

*For purposes of the NYSE and NASD ratings distribution disclosure requirements, our stock ratings of Outperform, Neutral, and Underperform most closely correspond to Buy, Hold, and Sell, respectively: however, the meanings are not the same, as our stock ratings are determined on a relative basis. (Please refer to definitions above.) An investor's decision to buy or sell a security should be based on investment objectives, current holdings, and other individual factors.

Credit Suisse's policy is to update research reports as it deems appropriate, based on developments with the subject company, the sector or the market that may have a material impact on the research views or opinions stated herein.

Credit Suisse's policy is only to publish investment research that is impartial, independent, clear, fair and not misleading. For more detail please refer to Credit Suisse's Policies for Managing Conflicts of Interest in connection with Investment Research: http://www.csfb.com/research-and-analytics/disclaimer/managing_conflicts_disclaimer.html

Credit Suisse does not provide any tax advice. Any statement herein regarding any US federal tax is not intended or written to be used, and cannot be used, by any taxpayer for the purposes of avoiding any penalties.

See the Companies Mentioned section for full company names.

Price Target: (12 months) for (ICL.TA)

Method: Our target price is based on 2011E EV/EBITDA of 11x.

Risks: Potash and phosphate fertiliser prices are volatile globally and any downturn would negatively influence the revenue line. The volatility in fertiliser prices and a greater than expected appreciation of the Israeli shekel are the risks we see to our target price.

Please refer to the firm's disclosure website at www.credit-suisse.com/researchdisclosures for the definitions of abbreviations typically used in the target price method and risk sections.

See the Companies Mentioned section for full company names.

Credit Suisse expects to receive or intends to seek investment banking related compensation from the subject company (ICL.TA) within the next 3 months.

Important Regional Disclosures

Singapore recipients should contact a Singapore financial adviser for any matters arising from this research report.

The analyst(s) involved in the preparation of this report have not visited the material operations of the subject company (ICL.TA) within the past 12 months.

Restrictions on certain Canadian securities are indicated by the following abbreviations: NVS--Non-Voting shares; RVS--Restricted Voting Shares; SVS--Subordinate Voting Shares.

Individuals receiving this report from a Canadian investment dealer that is not affiliated with Credit Suisse should be advised that this report may not contain regulatory disclosures the non-affiliated Canadian investment dealer would be required to make if this were its own report.

For Credit Suisse Securities (Canada), Inc.'s policies and procedures regarding the dissemination of equity research, please visit http://www.csfb.com/legal_terms/canada_research_policy.shtml.

As of the date of this report, Credit Suisse acts as a market maker or liquidity provider in the equities securities that are the subject of this report.

Principal is not guaranteed in the case of equities because equity prices are variable.

Commission is the commission rate or the amount agreed with a customer when setting up an account or at anytime after that.

To the extent this is a report authored in whole or in part by a non-U.S. analyst and is made available in the U.S., the following are important disclosures regarding any non-U.S. analyst contributors:

The non-U.S. research analysts listed below (if any) are not registered/qualified as research analysts with FINRA. The non-U.S. research analysts listed below may not be associated persons of CSSU and therefore may not be subject to the NASD Rule 2711 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

- Semyon Mironov, non-U.S. analyst, is a research analyst employed by Credit Suisse Securities (Europe) Limited.
- Mikhail Priklonsky, non-U.S. analyst, is a research analyst employed by Credit Suisse Securities (Europe) Limited.

For Credit Suisse disclosure information on other companies mentioned in this report, please visit the website at www.credit-suisse.com/researchdisclosures or call +1 (877) 291-2683.

Disclaimers continue on next page.

Israel Chemicals (ICL.TA)



This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Credit Suisse AG, the Swiss bank, or its subsidiaries or its affiliates ("CS") to any registration or licensing requirement within such jurisdiction. All material presented in this report, unless specifically indicated otherwise, is under copyright to CS. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of CS. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of CS or its affiliates.

The information, tools and material presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities or other financial instruments. CS may not have taken any steps to ensure that the securities referred to in this report are suitable for any particular investor. CS will not treat recipients as its customers by virtue of their receiving the report. The investments or services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about such investments or investment services. Nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise constitutes a personal recommendation to you. CS does not offer advice on the tax consequences of investment and you are advised to contact an independent tax adviser. Please note in particular that the bases and levels of taxation may change.

CS believes the information and opinions in the Disclosure Appendix of this report are accurate and complete. Information and opinions presented in the other sections of the report were obtained or derived from sources CS believes are reliable, but CS makes no representations as to their accuracy or completeness. Additional information is available upon request. CS accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that liability arises under specific statutes or regulations applicable to CS. This report is not to be relied upon in substitution for the exercise of independent judgment. CS may have issued, and may in the future issue, a trading call regarding this security. Trading calls are short term trading opportunities based on market events and catalysts, while stock ratings reflect investment recommendations based on expected total return over a 12-month period as defined in the disclosure section. Because trading calls and stock ratings reflect different assumptions and analytical methods, trading calls may differ directionally from the stock rating. In addition, CS may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and CS is under no obligation to ensure that such other reports are brought to the attention of any recipient of this report. CS is involved in many businesses that relate to companies mentioned in this report. These businesses include specialized trading, risk arbitrage, market making, and other proprietary trading.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgement at its original date of publication by CS and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments. Investors in securities such as ADR's, the values of which are influenced by currency volatility, effectively assume this risk.

Structured securities are complex instruments, typically involve a high degree of risk and are intended for sale only to sophisticated investors who are capable of understanding and assuming the risks involved. The market value of any structured security may be affected by changes in economic, financial and political factors (including, but not limited to, spot and forward interest and exchange rates), time to maturity, market conditions and volatility, and the credit quality of any issuer or reference issuer. Any investor interested in purchasing a structured product should conduct their own investigation and analysis of the product and consult with their own professional advisers as to the risks involved in making such a purchase. Some investments discussed in this report have a high level of volatility. High volatility investments may experience sudden and large falls in their value causing losses when that investment is realised. Those losses may equal your original investment. Indeed, in the case of some investments the potential losses may exceed the amount of initial investment, in such circumstances you may be required to pay more money to support those losses. Income yields from investments may fluctuate and, in consequence, initial capital paid to make the investment may be used as part of that income yield. Some investments may not be readily realisable and it may be difficult to sell or realise those investments, similarly it may prove difficult for you to obtain reliable information about the value, or risks, to which such an investment is exposed.

This report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of CS, CS has not reviewed the linked site and takes no responsibility for the content contained therein. Such address or hyperlink (including addresses or hyperlinks to CS's own website material) is provided solely for your convenience and information and the content of the linked site does not in any way form part of this document. Accessing such website or following such link through this report or CS's website shall be at your own risk.

This report is issued and distributed in Europe (except Switzerland) by Credit Suisse Securities (Europe) Limited, One Cabot Square, London E14 4QJ, England, which is regulated in the United Kingdom by The Financial Services Authority ("FSA"). This report is being distributed in Germany by Credit Suisse Securities (Europe) Limited Niederlassung Frankfurt am Main regulated by the Bundesanstalt fuer Finanzdienstleistungsaufsicht ("BaFin"). This report is being distributed in the United States by Credit Suisse Securities (USA) LLC; in Switzerland by Credit Suisse AG; in Canada by Credit Suisse Securities (Canada), Inc.; in Brazil by Banco de Investimentos Credit Suisse (Brasil) S.A. or its affiliates; in Mexico by Banco Credit Suisse (Mexico), S.A. (transactions related to the securities mentioned in this report will only be effected in compliance with applicable regulation); in Japan by Credit Suisse Securities (Japan) Limited, Financial Instrument Firm, Director-General of Kanto Local Finance Bureau (Kinsho) No. 66, a member of Japan Securities Dealers Association, The Financial Futures Association of Japan, Japan Securities Investment Advisers Association; elsewhere in Asia/Pacific by whichever of the following is the appropriately authorised entity in the relevant jurisdiction: Credit Suisse (Hong Kong) Limited, Credit Suisse Securities (Malaysia) Sdn Bhd, Credit Suisse AG, Singapore Branch, Credit Suisse Securities (India) Private Limited, Credit Suisse Securities (Europe) Limited, Seoul Branch, Credit Suisse AG, Taipei Securities Indonesia, and elsewhere in the world by the relevant authorised affiliate of the above. Research on Taiwanese securities produced by Credit Suisse Securities (Malaysia) Sdn. Bhd., to whom they should direct any queries on +603 2723 2020.

In jurisdictions where CS is not already registered or licensed to trade in securities, transactions will only be effected in accordance with applicable securities legislation, which will vary from jurisdiction to jurisdiction and may require that the trade be made in accordance with applicable exemptions from registration or licensing requirements. Non-U.S. customers wishing to effect a transaction should contact a CS entity in their local jurisdiction unless governing law permits otherwise. U.S. customers wishing to effect a transaction should do so only by contacting a representative at Credit Suisse Securities (USA) LLC in the U.S.

Please note that this report was originally prepared and issued by CS for distribution to their market professional and institutional investor customers. Recipients who are not market professional or institutional investor customers of CS should seek the advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. This research may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA or in respect of which the protections of the FSA for private customers and/or the UK compensation scheme may not be available, and further details as to where this may be the case are available upon request in respect of this report.

Any Nielsen Media Research material contained in this report represents Nielsen Media Research's estimates and does not represent facts. NMR has neither reviewed nor approved this report and/or any of the statements made herein.

If this report is being distributed by a financial institution other than Credit Suisse AG, or its affiliates, that financial institution is solely responsible for distribution. Clients of that institution should contact that institution to effect a transaction in the securities mentioned in this report or require further information. This report does not constitute investment advice by Credit Suisse to the clients of the distributing financial institution, and neither Credit Suisse AG, its affiliates, and their respective officers, directors and employees accept any liability whatsoever for any direct or consequential loss arising from their use of this report or its content.

Copyright 2010 CREDIT SUISSE AG and/or its affiliates. All rights reserved.

CREDIT SUISSE SECURITIES (Europe) Limited

Europe: +44 (20) 7888-8888